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Prion neuropathology follows the accumulation
of alternate prion protein isoforms after infective
titre has peaked
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Prions are lethal infectious agents thought to consist of multi-chain forms (PrPSc) of
misfolded cellular prion protein (PrPC). Prion propagation proceeds in two distinct
mechanistic phases: an exponential phase 1, which rapidly reaches a ﬁxed level of infectivity
irrespective of PrPC expression level, and a plateau (phase 2), which continues until clinical
onset with duration inversely proportional to PrPC expression level. We hypothesized that
neurotoxicity relates to distinct neurotoxic species produced following a pathway switch
when prion levels saturate. Here we show a linear increase of proteinase K-sensitive PrP
isoforms distinct from classical PrPSc at a rate proportional to PrPC concentration,
commencing at the phase transition and rising until clinical onset. The unaltered level of total
PrP during phase 1, when prion infectivity increases a million-fold, indicates that prions
comprise a small minority of total PrP. This is consistent with PrPC concentration not being
rate limiting to exponential prion propagation and neurotoxicity relating to critical
concentrations of alternate PrP isoforms whose production is PrPC concentration dependent.
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P
rions are infectious agents causing lethal neurodegenerative
diseases, such as Creutzfeldt–Jakob disease in humans, and
scrapie and bovine spongiform encephalopathy in animals,
following prolonged asymptomatic incubation periods1. In
humans, these can span decades and are followed by a rapidly
progressive, often stereotypic, clinical phase, which is invariably
fatal1,2. In inbred lines of laboratory mice, incubation periods
span months and yet are highly reproducible for a deﬁned line
with clinical onsets spanning only a few days.
In studies of mice intracerebrally infected with the Rocky
Mountain Laboratory (RML) prion strain, we have previously
demonstrated that prion propagation in the brain involves two
distinct phases3. In phase 1, prions propagate exponentially, not
rate limited by cellular prion protein (PrPC) concentration,
rapidly rising byB106-fold to reach a maximal prion titre, which
is also independent of PrPC concentration over the range we
studied. This is followed by a plateau phase (phase 2), which
determines time to clinical onset of disease, the duration of
which is inversely proportional to PrPC concentration.
Determination of prion titres at the beginning and end of the
plateau in FVB/N mice by mouse end-point titration bioassay
showed indistinguishable levels of infectivity3. Prion propagation
and neurotoxicity can therefore be uncoupled, arguing that prions
are not themselves directly neurotoxic. We hypothesized that
once prion propagation saturates, there is a mechanistic switch
from autocatalytic production of infectivity (phase 1) to a toxic
pathway where prions act as a catalytic surface for the production
of toxic species in a process now linearly dependent on PrPC
concentration3. The rate of production of such toxic PrP species
(previously designated PrPL for lethal4) would determine the time
to exceed local toxic thresholds and subsequent clinical onset.
According to the widely accepted protein-only hypothesis5,
prions are thought to comprise multi-chain forms of misfolded,
host-encoded, PrPC, referred to as PrPSc (refs 6,7) and are now
thought to propagate by an autocatalytic process of seeded
ﬁbrilization and ﬁssion8–10. It is increasingly recognized that such
processes may be involved in the pathogenesis of commoner
neurodegenerative conditions, including Alzheimer’s and
Parkinson’s diseases11.
The multi-chain forms of misfolded prion protein thought to
comprise infectious prions have been generally referred to as PrPSc
and originally deﬁned by their relative protease-resistance (with
characteristic band shift on western blotting due to deletion of an
amino-terminal fragment following treatment with proteinase K
(PK)) and detergent insolubility as compared with normal PrPC
(refs 7,12). However, it is becoming clear that there are multiple
disease-related forms of PrP, some of which are protease
sensitive13,14. Indeed, such protease-sensitive disease-related PrP
may constitute the majority of infectivity in some prion isolates14.
These species remain poorly deﬁned in physical terms and an
internationally agreed, even provisional, nomenclature is lacking.
As PrPSc is by deﬁnition protease resistant, we do not favour the
term protease-sensitive PrPSc (sPrPSc) (ref. 15). Here we simply
use the term ‘PK-sensitive disease-related PrP’ to refer to the
ensemble of PrP species seen in prion infection but which do not
meet the biochemical deﬁnition of ‘classical’ PrPSc.
In our previous studies of the kinetics of prion propagation, we
determined the brain prion titre at deﬁned intervals during the
incubation period in four types of mice with different PrPC
expression levels3. We have now proceeded to measure changes
in disease-related PrP isoforms in the brain in mice in both the
original3 and repeat time-course studies. We have developed an
assay to measure total PrP. This must comprise PrPC and all
disease-related isoforms (which are the sum of PK-sensitive and
PK-resistant (classical PrPSc) isoforms). By subtraction of levels
of classical PK-resistant PrPSc, any rise would represent the
ensemble of PK-sensitive disease-related PrP, assuming PrPC
levels are unchanged during infection. Prnp expression is known
to be unaltered during prion infection16,17. A recent study
reported an apparent fall in PrPC concentration towards the end
of the incubation period18; if conﬁrmed, this would suggest such a
subtraction method would underestimate the rise in levels of PK-
sensitive disease-related PrP late in phase 2. We have then sought
to determine how changes in levels of disease-related isoforms
related to the mechanistic phases we have described and to the
development of neuropathology.
Results
Levels of total PrP and classical PrPSc during prion infection.
In our previous study3, we intracerebrally inoculated large groups
of the following mice with RML mouse prions (30ml 1% brain
homogenate containing 105.8 intracerebral LD50 units) and groups
of ﬁve to six mice were killed at multiple deﬁned time points or at
the onset of clinical disease: inbred FVB/N mice (Prnpþ /þ ; wild-
type PrPC expression level); Prnp-null mice19 (Prnpo/o; no PrPC
expression; FVB/N background); hemizygous Prnp-null mice
(Prnpþ /o; 50% wild-type PrPC expression; FVB/N background)
and Tg20 transgenic mice20 (B8-fold wild-type PrPC expression
level; FVB/N background). Prion titre in mouse brain was
determined by scrapie cell assay (SCA) or SCA in end-point
format (scrapie cell endpoint assay (SCEPA)) for low-titre samples
as previously reported21 (Fig. 1). Prions were undetectable in
Prnpo/o mice, which are unable to propagate prions22, after 10
days, indicating clearance of the inoculum by this time and
allowing interpretation of de novo produced prions in the other
mouse lines3. In our earlier work, we had anticipated that prion
titres would principally rise late in the incubation period such that
relatively few timed culls were early in the incubation period3. We
have since repeated the original study with many more timed culls,
particularly in phase 1. The infectivity curves obtained were closely
similar to our earlier results (Fig. 2).
We then proceeded to measure changes in disease-related PrP
isoforms in the brain in these mice to determine how these related
to the mechanistic phases we have described and to the
development of neuropathology. Although our ultimate aim is
to isolate and structurally characterize the putative toxic PrP
species (PrPL), at this stage we do not know whether toxicity is
mediated by a single deﬁned species of high speciﬁc toxicity, or, at
the other extreme, relates to an ensemble of diverse species with a
generic toxicity. It appears that infectious prion strains constitute
a cloud or quasispecies10,23,24, and it is possible that infectious
and toxic PrP populations overlap. Given these uncertainties and
the lack of physical characterization of disease-related PrP
species, we modiﬁed for our purposes an enzyme-linked
immunosorbent assay (ELISA) that is capable of detecting all
PrP chains following their denaturation with heat and SDS14,25,26.
This assay therefore provides a measure of total PrP present in
brain homogenates and must necessarily comprise the sum of
normal PrPC and disease-related PrP generated during the
infection. The latter would comprise both classical PK-resistant
PrPSc and PK-sensitive disease-related PrP isoforms13,14,26. As
Prnp expression is unaltered16,17 and PrPC concentration does
not rise18 during prion infection, the rise in total PrP represents
the rise in levels of total disease-related PrP (including PK-
resistant and PK-sensitive forms). Levels of classical PK-resistant
PrPSc were also determined, thus enabling estimation of PK-
sensitive disease-related PrP isoform levels during the incubation
period (Fig. 1).
Remarkably, total PrP levels, although starting at different levels
in the three mouse lines due to their different PrPC expression
levels, were essentially unchanged throughout phase 1 in
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wild-type, Prnpþ /o and Tg20 mice, a period during which titres
rose in each case by B106-fold (Fig. 1). When prion titre had
reached plateau (marking the start of phase 2), total PrP levels
then rose in a linear manner throughout phase 2 with a gradient
approximately proportional to PrPC expression level (Fig. 1). In
agreement with previous studies, classical PrPSc represents only a
small fraction of total PrP levels at onset of clinical disease
and the majority of this is detected towards the end of phase 2
(Figs 1 and 3). Notably, in all three lines of mice, clinical onset
appears to ensue only once a closely similar level of total disease-
related PrP in the brain is reached (Figs 1 and 3). These data
suggest that a particular PrP isoform(s) that is generated in phase
2 must reach a critical threshold level to elicit neurotoxic effects,
irrespective of the level of PrPC expressed in the brain.
Correlation with onset of neuropathological changes. We then
sought to correlate changes in prion titre and disease-related PrP
isoforms with onset of neuropathological changes. To allow a
systematic neuropathological analysis, we repeated the original
time course using only the wild-type FVB mice and performed
timed culls with a considerably increased number of time points
(at 5-day intervals from post-inoculation day 5 to day 90, then at
days 125 and 140) to prepare suitable ﬁxed brain tissues for his-
tology and immunohistochemistry. All neuropathological scoring
was performed blind to sample identity. Prion titres were also
determined again at the same time points to ensure comparability
with the original experiment (Fig. 3). Prion titre had reached
plateau level by day 75. Spongiform vacuolation of the neuropil is
a key speciﬁc histological characteristic of prion disease. It appears
to correlate with early disease activity and indeed early spongiosis
is completely reversible on targeted knockout of PrPC expression
in neuroinvasive RML prion infection of FVB mice27. Uniform
(12/12 mice), albeit mild, spongiosis was only seen at post-
infection day 85 and was restricted to the thalamus and
hippocampus. As expected for the RML prion strain, spongiosis
then extended to the basal ganglia by day 90 and had become of
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Figure 1 | Levels of total PrP and PrPSc in the brain during prion infection.
Three different lines of FVB/N mice: Prnpþ /0 with 50% wild-type PrPC
expression (i); Prnpþ /þ with wild-type PrPC expression (ii); and Tg20 with
Beightfold overexpression of PrPC (iii) were intracerebrally infected with
RML prions. Mean incubation periods are indicated by arrows and were (in
days±s.d.): Prnpþ /0, 258±23.5; Prnpþ /þ , 137±1.5; and Tg20, 59.5±2.0.
Mice were culled at deﬁned time points or at clinical onset of disease. Prion
titres (log tissue-culture infectious units per gram brain; bars indicate s.e.m.
and in some cases are smaller than the symbols used to designate mean)
are as described previously3 (closed circles; dotted lines). Total PrP
comprising PrPC, classical PK-resistant PrP (PrPSc) and disease-related but
PK-sensitive PrP isoforms were determined by ELISA (closed circles; solid
lines). In addition, PrPSc was quantiﬁed after PK digestion by ELISA (open
circles; solid lines). Total PrP and PrPSc levels are presented as a ratio
relative to a clinical end point reference; bars indicate s.e.m and, in some
cases, are smaller than the symbol used to designate mean; group sizes
were three to six.
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Figure 2 | Repeat kinetic time courses showing infectivity in three
different lines of mice after prion infection with a high saturation of time
points. Three different lines of FVB/N mice: Tg20 with Beightfold
overexpression of PrPC in blue, Prnpþ /þ with wild-type PrPC expression in
grey and Prnpþ /0 with 50% wild-type PrPC expression in red, were infected
with RML prions. Mice were culled at deﬁned time points or at onset of
disease and prion titres determined using scrapie cell assay (SCA) or
scrapie cell assay in end-point format (SCEPA) for low-titre samples.
Prion titres (log tissue-culture infectious units per gram brain; bars
indicate s.e.m. and, in some cases, are smaller than the symbols used to
designate mean) are closely similar to those described previously3. Normal
interval regression was used to calculate mean and s.e.m for timed culls
where one or more samples were below assay sensitivity cut-off. This only
applied to samples up to day 37 of the time courses. All samples from three
timed culls in the PrnPþ/þ time course (5, 10 and 13 days) were below
assay sensitivity cut-off and are not shown.
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moderate severity and involved virtually all grey matter areas by
day 140 (Figs 4 and 5). No spongiform vacuolation was detected in
any mice before post-infection day 65 when small subtle vacuoles
in the hippocampus and thalamus were seen in 4/12 animals on
haematoxylin and eosin-stained sections (Fig. 5). The uniform
appearance of speciﬁc spongiform pathology only in phase 2 is
consistent with a lack of direct neurotoxicity of infectious prions
and the hypothesized production of toxic species via a distinct
pathway once prion propagation has saturated. PrP immuno-
histochemistry using anti-PrP monoclonal antibody ICSM35
revealed evidence of residual inoculum in some animals from
day 5 to 30, but without synaptic PrP deposition that is
characteristic of prion infection. Very subtle occasional synaptic
deposits28 were seen in some mice from day 35 to 50; consistent
deposits were seen in the thalamus and cortex in all mice from day
55 (Fig. 5). Whether these subtle PrP deposits seen in phase 1
simply represent infectious prions is unknown. Microglia were
assessed using antibody Iba1 and the earliest reproducible
activation was seen at day 35 in the thalamus in some animals.
Activation was however well established in all animals by day 65.
Synaptophysin immunoreactivity was assessed to detect synaptic
loss. The ﬁrst clear reduction of synaptic density and granular
normality was detected at day 125 (Fig. 5).
Discussion
The basis of neurotoxicity in prion neurodegeneration, its
relationship to the prolonged clinically silent incubation periods
and the remarkable synchronicity of clinical onset have remained
obscure. Although classical PrPSc rises towards the end of the
incubation period and has been considered a candidate
neurotoxic species, the well-documented existence of subclinical
carrier states of prion infection, where conventional mice with
normal PrPC expression live a typical lifespan despite harbouring
levels of classical PrPSc and prion titres similar to those of mice
with end-stage clinical disease4,29–33, argues against this.
These ﬁndings are consistent with the general model of prion
propagation and neurotoxicity in which prion infectivity and
toxicity are mediated by different PrP species, which are the
product of distinct pathways3,10. According to this model,
production of neurotoxic species is triggered when the
exponential phase (phase 1) of prion propagation saturates
(following depletion of a key co-factor or occupancy of available
replication sites). The fact that this explosive rise in prion titre is
not rate limited by PrPC concentration is consistent with the
absence of a rise of total PrP during phase 1 arguing that
infectious prions comprise a small minority of available PrP. In
phase 2, there is a linear rise in PK-sensitive disease-related PrP
isoforms, a mechanistically distinct process rate limited by, and
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Figure 3 | Repeat time course of RML prion infection in FVB/N wild-type
mice used for detailed neuropathological analysis. FVB/N mice were
infected with RML prions and the mean incubation period for these mice
was (in days±s.d.) 168±2.5. Mice were culled at deﬁned time points or at
onset of disease and prion titres were determined using scrapie cell assay
(SCA) or scrapie cell assay in end-point format (SCEPA) for low-titre
samples. Prion titres (log tissue-culture infectious units per gram brain; bars
indicate s.e.m. and, in some cases, are smaller than the symbols used to
designate mean) are closely similar to those described previously3 (closed
circles; dotted lines). Normal interval regression was used to calculate
mean and s.e.m for timed culls where one or more samples were below
assay sensitivity cut-off. This only applied to samples up to day 30 of the
time course. All samples from two timed culls in the infectivity time course
(5 and 15 days) were below assay sensitivity cut-off and therefore are not
shown. Total PrP comprising PrPC, classical PK-resistant PrP (PrPSc) and
disease-related but PK-sensitive PrP isoforms were determined using ELISA
(closed circles; solid lines). In addition, PrPSc was quantiﬁed after PK
digestion by ELISA (open circles; solid lines). Total PrP and PrPSc levels are
presented relative to a clinical end-point reference; bars indicate s.e.m and,
in some cases, are smaller than symbol used to designate mean; group
sizes were four to six.
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Figure 4 | Temporal development of spongiform neuropathology during
prion infection. FVB/N mice were intracerebrally infected with RML prions
and the mean incubation period was (in days±s.d.) 168±2.5. Mice were
culled at deﬁned time points or at onset of clinical disease and brain
sections stained with haematoxylin and eosin (H&E). Spongiform
vacuolation was absent in all mice at day 60 (a), present at a mild level in
the thalamus and hippocampus in 3/10 mice at day 80 (b) and in 8/8 mice
at day 90 (c). By day 140, all mice showed moderate and widespread
spongiosis affecting the cortex, midbrain and basal ganglia, in addition to
hippocampus and thalamus (d). (a–d) H&E staining in the thalamus. (a’–d’)
Schematics showing regional distribution of spongiosis. The boxes
correspond to the number of mice in each group and the dark shaded boxes
represent the number of animals positive for the neuropathology described.
Scale bar, 50mm (a–d).
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Figure 5 | Evolution of pathological changes in the brain during prion infection. FVB/N mice were intracerebrally inoculated with RML prions and
groups of mice culled at deﬁned time points or at onset of clinical prion disease. The mean incubation period was 168±2.5 days (±s.d.). Fixed brains from
each timed cull were analysed for spongiform change by haematoxylin and eosin (H&E) staining together with immunohistochemical analyses for
abnormal PrP deposition, microglia activation and neuronal loss (monitored by synaptophysin staining). Schematic representations of the brain taken at
various time points show the evolution of pathological changes throughout the disease course. Numbers shown next to the schematics report the
number of animals in the group positive for the pathology shown as a fraction of the total number of animals in each group.
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directly proportional to, PrPC concentration. Clinical onset
occurs at a similar level of PK-sensitive disease-related PrP
isoforms irrespective of PrPC expression level (Fig. 6). The
classical neuropathological features of prion disease, indicative of
the presence of neurotoxic species, are only detected once phase 2
is well established. The precise temporal relationship between
production of such neurotoxic species, reaching critical
concentrations at critical sites, and onset of neuropathology
cannot be deﬁned by these experiments, and will ultimately
require isolation of PrPL species and direct studies of
neurotoxicity. However, such isolation and physical
characterization of neurotoxic species, as with other
neurodegenerative diseases, is likely to prove technically
demanding. Such species may be transitory and inherently
labile. In addition, as discussed above, it is unknown whether
the majority of the PK-sensitive disease-related PrP isoforms
constitute generic toxic material or whether at the other extreme a
low abundance speciﬁc sub-species of deﬁned structure and
receptor interaction with high speciﬁc toxicity constitutes the
hypothetical PrPL. An essential prerequisite will be the
development of a robust in vitro assay for such neurotoxic
activity with a sufﬁcient dynamic range to facilitate fractionation
and isolation of such species. These data also suggest that the
term PrPSc, often used synonymously with infectivity, should be
restricted to material as classically biochemically deﬁned7,12. Such
classical PrPSc only constitutes a small (variable) fraction of total
disease-related PrP isoforms and its proportional contribution to
both infectivity and neurotoxicity remains unclear.
All the common neurodegenerative diseases involve accumula-
tion of aggregated misfolded host proteins and it is increasingly
proposed that seeded protein aggregation (or ‘prion-like mechan-
isms’) may be involved in their pathogenesis and/or spread of
pathology throughout the neuraxis. Experimental prion disease
offers major advantages in studying neurodegenerative processes,
because prion diseases naturally affect many mammalian
species, including laboratory rodents, avoiding the inherent
limitations of mouse models of other neurodegenerative diseases
and, crucially, because of the predictable incubation periods
and tools established to determine prion strain properties and
accurately measure titre1. If comparable tools can be developed
for the commoner neurodegenerative conditions such as
Alzheimer’s and Parkinson’s diseases, it will be interesting to
investigate whether similar mechanistic relationships between
seeding activity and neurotoxicity are also involved.
Methods
All experimental procedures involving prions were carried out in microbiological
containment level 3 facilities with strict adherence to safety protocols.
Prion inoculation of mice. Work with mice was performed under licence granted
by the UK Home Ofﬁce and conformed to the University College London insti-
tutional and ARRIVE guidelines. RML prion inoculum (I6200) was prepared and
titrated14, and mice (female 6–9 weeks old) were intracerebrally inoculated and
monitored as described previously3. Groups of 5–12 mice were killed at multiple
deﬁned time points or at onset of clinical disease. Brains were removed and divided
sagittally with half-frozen at  70 C and half-ﬁxed in 10% (v/v) formal buffered
saline. Brain homogenates (10% (w/v)) were prepared from frozen specimens in
sterile Dulbecco’s PBS lacking Ca2þ and Mg2þ ions (D-PBS) and stored as
aliquots at  70 C.
Prion bioassay. PK1 cells (sub-clone PK1/2), a line derived from N2a cells that are
highly susceptible to RML prions21 were routinely grown into OFCS medium (Opti-
MEM, containing 10% FCS; 100Uml 1 penicillin and 100mgml 1 streptomycin;
Invitrogen, UK) using 15 cm Petri dishes. Prion infectivity was assayed using two
modiﬁed automated protocols based on the original published methods21, the
SCEPA and the automated SCA (ASCA). The SCEPA is capable of detecting sample
infectivity in a range down toB103 tissue culture infectious units (TCIU) ml 1 of
10% (w/v) brain homogenate21, while the ASCA is typically used to detect infectivity
above 104.5 TCIUml 1 in 10% (w/v) brain homogenate. The day before infection,
PK1/2 cells were seeded into 96-well plates (18,000 cells in 260ml OFCS; Costar ﬂat
bottom 96-well plates; Corning, UK) and kept at 37 C in a 5% CO2 incubator. The
following day, 10ml of brain homogenate appropriately diluted in OFCS was applied
to the cells. A serial dilution of a reference 10% (w/v) RML brain homogenate
(maximal titre of 107.7 TCIUml 1 determined by SCEPA) was applied in parallel.
Typically, 10% (w/v) brain homogenate was used in the range of 1 10 3 to
1 10 5 dilution for SCEPA and 3 10 4 to 3 10 6 dilution for ASCA. Three
days after infection, an automated platform (Biomek FX liquid handling robot;
Beckman Coulter) was used to split cells. For the SCEPA protocol, cells were split
into 96-well plates containing fresh OFCS at ratios of 1:3 on days 3, 5 and 7, followed
by splitting 1:8 at days 10, 13, 17 and 21 post infection, while the ASCA was split at a
ratio of 1:8 on days 3, 6, 10 and 14 post infection. ELISpot plates (96-well–
polyvinylidene diﬂuoride membrane plates; Millipore, UK) were prepared from the
SCEPA assays on days 17 and 21 post infection and on days 10 and 14 post infection
for the ASCA assays (25,000 cells per well). The plates were vacuum drained and
dried at 50 C after which 60ml of 1mgml 1 PK (Roche, UK) in lysis buffer (50mM
Tris HCl, pH 8, containing 150mM NaCl, 0.5% (w/v) sodium deoxycholate and
0.5% (v/v) Triton X-100) was added to each well and incubated for 60min at 40 C.
The plates were washed (2 160ml PBS) after which 120ml of 3M guanidinium
thiocyanate prepared in 10mM Tris HCl, pH 8.0, was added to each well for 20min.
The wells were washed (7 160 ml PBS) and 150 ml of Superblock dry blend blocking
buffer (Perbio, UK) was added to each well and incubated for 1 h. Following vacuum
removal of Superblock, each well was incubated with 0.55mgml 1 anti-PrP
monoclonal antibody ICSM18 (D-Gen Ltd, London) prepared in TBST (10mM Tris
HCl, pH 8, 150mM NaCl, 0.1% (v/v) Tween 20) containing 1% (w/v) non-fat dry
milk for 1 h. After washing (5 160ml TBST), wells were incubated for 1 h with
60ml goat anti-mouse alkaline phosphatase-conjugated anti-IgG1 (Southern
Biotechnology Associates, USA) diluted 1:8,000 in TBST-1% (w/v) non-fat dry milk.
Following washing (5 160ml TBST), wells were incubated for 35min with 50ml AP
dye (Bio-Rad, USA). The plates were then washed twice with water, dried and stored
at  20 C. Spot counts (reporting PK-resistant PrP-positive cells) were determined
with a Zeiss KS Elispot system (Stemi 2000-C stereo microscope equipped with a
Hitachi HV-C20A colour camera, a KL 1,500 LCD scanner and Wellscan software
from Imaging Associates, Oxfordshire, UK). Normal interval regression was used to
calculate mean and s.e.m. for the groups that contained points below assay sensitivity
cut-off. If all samples in a timed group were below assay sensitivity cut-off, the group
was excluded from further analyses.
ELISA for total PrP. PrP levels in brain homogenate were determined by ELISA as
previously described14,26, but with adaptations. A pooled preparation of 10% (w/v)
terminal RML mouse brain homogenate (I8700) of known prion infectivity titre26
was diluted into D-PBS. These samples were used to generate standard curves of
ﬂuorescence versus I8700 concentration, and were processed in parallel with
unknown samples. PrP levels in unknown samples were expressed relative to the
I8700 reference preparation. The protein concentration of 10% (w/v) brain
homogenate was determined using the Bicinchoninic acid assay kit (Thermo
Scientiﬁc, Rockford, IL, USA) according to the manufacturer’s instructions and
aliquots subsequently adjusted with D-PBS to give a ﬁnal protein concentration of
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Figure 6 | Diagrammatic representation of kinetics of prion propagation
and toxicity. Prion replication (dotted lines) is exponential in phase 1 until a
limiting titre of prions (infectivity plateau) is attained independent of PrPC
expression level. Plateau length (phase 2) is inversely proportional to PrPC
expression level3. During phase 1, total PrP levels do not signiﬁcantly
change from the starting PrPC level before infection (Fig. 1). PK-sensitive
disease-related PrP is total PrP minus starting PrPC level (by deﬁnition zero
in all three mouse lines before infection) and classical PrPSc. At the phase
transition, PK-sensitive disease-related PrP isoforms begin to accumulate
(solid lines). The rise of PK-sensitive disease-related PrP appears linear and
approximately proportional to mouse PrPC expression level (Figs 1 and 3).
Onset of clinical disease occurs when a critical level of toxic species is
reached, which is closely similar in each mouse line.
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7mgml 1. Twenty-microlitre aliquots of these samples were treated with an equal
volume of either D-PBS alone or D-PBS containing 50mgml 1 PK and incubated at
37 C for 1 h. This concentration of PK (at a ratio of 1:140 total brain protein by
weight) was used to ensure complete digestion of PrPC in overexpressing Tg20
transgenic mice and to retain only the most PK-resistant abnormal PrP conformers
classically designated as PrPSc7. After addition of 1 ml 100mM 4-(2-aminoethyl)-
benzenesulphonyl ﬂuoride prepared in water and 1ml 20% (w/v) SDS prepared in
water, the samples were heated at 100 C for 10min. Twenty microlitres of the
denatured samples were then diluted into ELISA capture buffer (50mM Tris/HCl,
pH 8.4, containing 2% (v/v) Triton X-100, 2% (w/v) sodium lauroylsarcosine and
2% (w/v) BSA (fraction V, protease free, Sigma)) between 30 and 150 times for
analysis. The use of multiple dilutions ensured that ﬂuorescence measurements
generated by unknown samples could be correlated with the linear range of the
standard curves of I8700. Microtitre plates (Microlon 96W, Greiner Bio-One) were
coated overnight with anti-PrP monoclonal antibody ICSM18 (D-Gen Ltd) diluted
in carbonate coating buffer (250 ng antibody per well). The wells were blocked using
Superblock T20 (PBS) blocking buffer (Thermo Scientiﬁc) and incubated with
constant agitation for 1 h at 37 C. Aliquots (50 ml) of the diluted samples were
transferred into the wells of the plates and incubated with constant agitation at 37 C
for 1 h. Wells were washed with 3 300ml of PBS containing 0.05% (v/v) Tween 20
using an automated microplate washer, followed by the addition of 100ml of PBS
containing 1% (v/v) Tween 20 and 1mgml 1 biotinylated anti-PrP monoclonal
antibody ICSM 35 (D-Gen Ltd). Following incubation at 37 C for 15min with
constant agitation, wells were washed as detailed above, followed by the addition of
100ml of PBS containing 1% (v/v) Tween 20 and a dilution of streptavidin–
horseradish-peroxidase conjugate (1:10,000 dilution; Thermo Scientiﬁc). After
incubation at 37 C for 15min with constant agitation, wells were washed with
4 300ml of PBS containing 0.05% (v/v) Tween 20. Wells were developed using
QuantaBlu Fluorogenic Peroxidase substrate kit according to the manufacturer’s
instructions (Thermo Scientiﬁc). Fluorescence was measured on a Tecan inﬁnite
M200 spectra image microplate reader (lex¼ 313 nm, lem¼ 398nm).
Neuropathology and immunohistochemistry. Brain ﬁxed in 10% buffered for-
mol-saline was immersed in 98% formic acid for 1 hour and parafﬁn wax
embedded. Serial sections (4-mm-thick) were pretreated by boiling for 10min in a
low ionic strength buffer (2.1mM Tris, 1.3mM EDTA, 1.1mM sodium citrate,
pH 7.8) before exposure to 98% formic acid for 5min. Abnormal PrP accumulation
was examined using anti-PrP monoclonal antibody ICSM 35 (D-Gen Ltd).
Microglial activation was examined using an ionized calcium binding adaptor
molecule 1 (Iba1) antibody (Wako Pure Chemical Industries, Ltd) and synapto-
physin was examined using rabbit polyclonal antibodies (Z66, Life Technologies).
All immunohistochemistry was performed on automated immunohistochemistry
staining machines (Ventana Medical Systems Inc., Tucson, Arizona) using pro-
prietary secondary detection reagents (Ventana Medical Systems Inc.) before
development with 303-diaminobenzedine tetrachloride as the chromogen34.
Conventional methods were used for Harris haematoxylin and eosin staining.
Appropriate positive and negative controls were used throughout. Photographs
were taken on an ImageView digital camera and composed with Adobe Photoshop.
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